Related references
Note: Only part of the references are listed.Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing α1-Antitrypsin: Interim Results
Terence R. Flotte et al.
HUMAN GENE THERAPY (2011)
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B
Valder R. Arruda et al.
BLOOD (2010)
Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
Virginia Haurigot et al.
MOLECULAR THERAPY (2010)
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells
Federico Mingozzi et al.
BLOOD (2009)
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B
Haiyan Jiang et al.
MOLECULAR THERAPY (2006)
Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model
VR Arruda et al.
BLOOD (2005)
Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1
VR Arruda et al.
BLOOD (2004)
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
CS Manno et al.
BLOOD (2003)
Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy
RW Herzog et al.
HUMAN GENE THERAPY (2002)
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
MA Kay et al.
NATURE GENETICS (2000)
Share Paper
